Journal article
Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis
- Abstract:
-
PAC203 is a randomized dose-finding study of pacritinib, an oral JAK2/IRAK1 inhibitor, in patients with advanced myelofibrosis who are intolerant of or resistant to ruxolitinib. Patients were randomized 1:1:1 to pacritinib 100 mg once per day, 100 mg twice per day, or 200 mg twice per day. Enhanced eligibility criteria, monitoring, and dose modifications were implemented to mitigate risk of cardiac and hemorrhagic events. Efficacy was based on ≥35% spleen volume response (SVR) and ≥50% reduct...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
Bibliographic Details
- Publisher:
- American Society of Hematology Publisher's website
- Journal:
- Blood Advances Journal website
- Volume:
- 4
- Issue:
- 22
- Pages:
- 5825-5835
- Publication date:
- 2020-11-24
- Acceptance date:
- 2020-10-14
- DOI:
- EISSN:
-
2473-9537
- ISSN:
-
2473-9529
- Pmid:
-
33232476
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
1147843
- Local pid:
- pubs:1147843
- Deposit date:
- 2021-01-21
Terms of use
- Copyright holder:
- American Society of Hematology
- Copyright date:
- 2020
- Rights statement:
- © 2020 by The American Society of Hematology.
- Notes:
- This is the publisher's version of the article. The final version is available online from the American Society of Hematology at: https://doi.org/10.1182/bloodadvances.2020003314
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record